Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

M. Korsic



Author of

  • +

    P2.24 - Poster Session 2 - Supportive Care (ID 157)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Supportive Care
    • Presentations: 1
    • +

      P2.24-013 - Efficacy and safety of erlotinib in Croatian patients (ID 963)

      09:30 - 09:30  |  Author(s): M. Korsic

      • Abstract

      Background
      Background: Erlotinib is inhibitor of epidermal growth factor receptor tyrosine-kinase activity that has been shown to significantly increase survival, delayed symptom progression and improve quality of life in previously treated advanced non-small cell lung cancer (NSCLC). Here we report safety and efficacy data from open label, phase IV trial of erlotinib in Croatian population.

      Methods
      Methods: patients with advanced NSCLC who had failed prior chemotherapy were treated with oral erlotinib 150 mg daily until disease progression or unacceptable toxicity.

      Results
      Results: a total of 384 patients (276 men and 108 women, mean age 62) with advanced NSCLC were enrolled in the study from 2006 to 2012 in 10 centers in throughout Croatia. Patient characteristics: Non-squamous NSCLC had 57% of patients, squamous NSCLC 32% and NOS 11%; active smokers 41%, former and/or never smokers 57%; ECOG 0 36%, ECOG 1 54%, ECOG 2 7%, ECOG 3 1%. Most of the patients (83%) received erlotinib in third line of treatment. Progression-free survival (PFS) was 2,3 months showed trend to improved PFS in patients with squamous compared to non-squamous NSCLC (3,7 vs. 2,1 months). PFS in non-smokers was longer than in smokers (2,6 vs. 2,1 months). Disease control rate after two cycles of treatment was 40%; most patients had stable disease. Most common adverse event (AE) was rash which developed in 58% of patients and diarrhea in 28%. Most of AEs were grade I and II. Grade III rash developed only in 10% of patients.

      Conclusion
      Conclusion: These data confirmed favorable efficacy and safety profile even in non-selected NSCLC Croatian patients, including patients with squamous cell lung cancer.